2018 Pipeline Insights for Hyperuricemia - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Sep 7, 2018--The “Hyperuricemia - Pipeline Insight, 2018” drug pipelines has been added to ResearchAndMarkets.com’s offering.
This report offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Hyperuricemia development.
The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type
Pipeline Products covered across the following Developmental Stages:Clinical Non-clinical Inactive: Discontinued and/or Dormant
ScopeThe report provides a snapshot of the pipeline development for Hyperuricemia The report covers pipeline activity across the complete product development cycle i.e. clinical, pre-clinical and discovery stages for Hyperuricemia The report provides pipeline product profiles which includes product description, developmental activities, licensors & collaborators and chemical information Provides pipeline assessment by monotherapy and combination therapy products, stage of development, route of administration, and molecule type for Hyperuricemia The report also covers the dormant and discontinued pipeline projects related to Hyperuricemia
Key Topics Covered
1. Report Introduction
2. Hyperuricemia Overview
3. Pipeline TherapeuticsAn Overview of Pipeline Products for Hyperuricemia
4. Comparative Analysis
5. Products in Clinical Stage
5.1 Drug Name: Company NameProduct Description Research and Development Product Development Activities
6. Products in Pre-Clinical and Discovery Stage
6.1 Drug Name: Company NameProduct Description Research and Development Product Development Activities
7. Therapeutic AssessmentAssessment by Route of Administration Assessment by Stage and Route of Administration Assessment by Molecule Type Assessment by Stage and Molecule Type
8. Inactive Products
8.1 Drug Name: Company NameProduct Description Research and Development Product Development Activities
Companies FeaturedAstraZeneca PLC CymaBay Therapeutics Kissei Pharmaceutical Co. LG Life Sciences Nippon Chemiphar Co. Polaris Pharmaceuticals Takeda Pharmaceutical Company Limited and more...
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/687nlz/2018_pipeline?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20180907005279/en/
Laura Wood, Senior Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Hematological Drugs
INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2018.
PUB: 09/07/2018 10:16 AM/DISC: 09/07/2018 10:16 AM